NDA 206110 · Fresenius Kabi USA
Caspofungin Acetate
Caspofungin Acetate · Intravenous
Last checked: Nov 20, 2026Latest source record: Apr 1, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Dec 30, 2016
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
67
24 Phase 3, 3 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Caspofungin" as an intervention, any sponsor and status, largest first.
- Caspofungin Study for Fungal Infections in Adults in Critical Care SettingsPivotal-lookingTerminated
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00095316 · 1,200 participants (planned) · Start Oct 2004
Drug: Caspofungin · For: Candidiasis
Sites: Birmingham, Alabama; Los Angeles, California; Torrance, California · 26 sites in all
- Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care UnitsPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00099775 · 1,200 participants · Start Dec 2004
Drug: Caspofungin · For: Candidiasis
Sites: Bethesda, Maryland
- Study of Micafungin in Patients With Invasive Candidiasis or CandidemiaPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00105144 · 611 participants · Start Sep 2004 · Primary completion Apr 2006
Drug: Micafungin; Caspofungin · For: Candidiasis; Candidemia
Sites: Birmingham, Alabama; Little Rock, Arkansas; Los Angeles, California · 167 sites in all
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow TransplantationPivotal-lookingCompleted
Mundipharma Research LimitedIndustry
NCT04368559 · 602 participants · Start May 11, 2020 · Primary completion Jan 29, 2026
Drug: Rezafungin for Injection; Posaconazole and 4 more · For: Candidemia; Mycoses; Fungal Infection and 7 more
Sites: Birmingham, Alabama; Los Angeles, California; Stanford, California · 53 sites in all
- Empirical Versus Preemptive Antifungal TherapyPivotal-lookingCompleted
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT01288378 · 556 participants · Start Mar 2012 · Primary completion Apr 4, 2019
Drug: caspofungin acetate · For: Fungal Infection; Leukemia; Myelodysplastic Syndromes
Sites: Bruges, Belgium; Brussels, Belgium; Leuven, Belgium · 16 sites in all
- Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid LeukemiaPivotal-lookingCompleted
Children's Oncology GroupResearch network
NCT01307579 · 517 participants · Start Apr 4, 2011 · Primary completion Jun 30, 2018
Drug: Caspofungin Acetate; Fluconazole · For: Acute Myeloid Leukemia; Adult Acute Monoblastic Leukemia; Adult Acute Monocytic Leukemia and 25 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 179 sites in all
- Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal CandidiasisPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00665639 · 454 participants · Start Jun 2004 · Primary completion Dec 2004
Drug: micafungin; caspofungin · For: Candidiasis, Oral
Sites: Buenos Aires, Argentina; Córdoba, Argentina; Neuquén, Argentina · 31 sites in all
- Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida InfectionsPivotal-lookingCompleted
Astellas Pharma IncAstellas (ALPMY)
NCT00413218 · 450 participants · Start Mar 8, 2007 · Primary completion Mar 3, 2015
Drug: Isavuconazole; Caspofungin and 1 more · For: Candidiasis, Invasive; Candidemia; Mycoses
Sites: Birmingham, Alabama; Palm Desert, California; Sacramento, California · 113 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Caspofungin Acetate (Caspofungin Acetate)
2024 spending
$1.4M
Beneficiaries
1,263
3,809 claims
Per beneficiary
$1,099
$12.81 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,439,014 |
| 2021 | $1,895,179 |
| 2022 | $1,931,343 |
| 2023 | $1,818,314 |
| 2024 | $1,388,495 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
Thompson GR, Soriano A, Cornely OA, et al. · Lancet 2023 · Randomized Controlled Trial, Multicenter Study
- Histoplasmosis: A systematic review to inform the World Health Organization of a fungal priority pathogens list.
Dao A, Kim HY, Halliday CL, et al. · Med Mycol 2024 · Systematic Review
- Echinocandin antifungal drugs.
Denning DW · Lancet 2003 · Clinical Trial, Comparative Study
- The impact of extracorporeal membrane oxygenation on antifungal pharmacokinetics: A systematic review.
Jendoubi A, Pressiat C, De Roux Q, et al. · Int J Antimicrob Agents 2024 · Systematic Review
- Efficacy and safety of caspofungin in children: systematic review and meta-analysis.
Rosanova MT, Bes D, Serrano Aguilar P, et al. · Arch Argent Pediatr 2016 · Meta-Analysis, Systematic Review
- Length of hospital and intensive care unit stay in patients with invasive candidiasis and/or candidemia treated with rezafungin: a pooled analysis of two randomised controlled trials.
Honoré PM, Bassetti M, Cornely OA, et al. · Crit Care 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Fresenius Kabi USA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.